Conformational polymorphism and cellular toxicity of IAPP and βAP domains

Journal of Structural Biology

Volumn 166, Issue 2, 2009, Pages 116-125

  Andrews, Maneesha E ^a,b   Inayathullah, N Mohammed ^a   Jayakumar, Rajadas ^a   Malar, E J Padma ^b  

^a CENTRAL LEATHER RESEARCH INSTITUTE   (India)

^b UNIVERSITY OF MADRAS   (India)

Author keywords

Alzheimer's disease; Amyloid disease; Conformational polymorphism; Non insulin dependent diabetes mellitus; Proteasome; Protein misfolding; Suc LLVF AMC

Indexed keywords

AMYLIN; AMYLOID BETA PROTEIN; PEPTIDE FRAGMENT; PROTEASOME; TETRAPEPTIDE; TRIFLUOROETHANOL;

ANIMAL CELL; ARTICLE; CONFORMATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME POLYMORPHISM; INHIBITION KINETICS; MICROENVIRONMENT; NONHUMAN; PANCREAS CELL; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; RAT;

AMINO ACID SEQUENCE; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; CELLS, CULTURED; CIRCULAR DICHROISM; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TRIFLUOROETHANOL;

EID: 63649130831     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2008.12.011     Document Type: Article

References (54)

1. Albert J.S., and Hamilton A.D. Stabilization of helical domains in short peptides using hydrophobic interactions. Biochemistry 34 (1995) 984-990
2. Azriel R., and Gazit E. Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. J. Biol. Chem. 276 (2001) 34156-34161
3. Bennett E.J., Bence N.F., Jayakumar R., and Kopito R.R. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol. Cell 17 (2005) 351-365
4. Bennett R.G., Duckworth W.C., and Hamel F.G. Degradation of amylin by insulin-degrading enzyme. J. Biol. Chem. 275 (2000) 36621-36625
5. Bennett R.G., Hamel F.G., and Duckworth W.C. Insulin inhibits the ubiquitin-dependent degrading activity of the 26S proteasome. Endocrinology. 141 (2000) 2508-2517
6. Clark A., Cooper G.J., Lewis C.E., Morris J.F., Willis A.C., Reid K.B., and Turner R.C. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet ii (1987) 231-234
7. Cooper G.J., Willis A.C., Clark A., Turner R.C., Sim R.B., and Reid K.B. Purification and characterization of a peptide from amyloid rich pancreases of type II diabetic patients. Proc. Natl. Acad. Sci. USA 30 (1987) 887-892
8. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res. 4 (2007) 147-152
9. D'Alessio D.A., Verchere C.B., Kahn S.E., Hoagland V., Baskin D.G., Palmiter R.D., and Ensinck J.W. Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43 (1994) 1457-1461
10. Duckworth W.C., Bennett R.G., and Hamel F.G. A direct inhibitory effect of insulin on a cytosolic proteolytic complex containing insulin-degrading enzyme and multicatalytic proteinase. J. Biol. Chem. 269 (1994) 24575-24580
11. Fox N., Schrementi J., Nishi M., Ohagi S., Chan S.J., Heisserman J.A., Westermark G.T., Leckstrom A., Westermark P., and Steiner D.F. Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM). FEBS Lett. 323 (1993) 40-44
12. Ganesh S., and Jayakumar R. Monolayer formation of short helical turn forming peptide derivatives at the air-water and air-solid interfaces. Chem. Phys. Lett. 380 (2003) 681-688
13. Goto S., and Kurochkin I.V. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 345 (1994) 33-37
14. Gregori L., Fuchs C., Maria E., Pereira F., Van Nostrand W.E., and Goldgaber D. Amyloid-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. Chem. 270 (1995) 19702-19708
15. Gregori L., Hainfeld J.F., Simon M.N., and Goldgaber D. Binding of amyloid β protein to the 20 s proteasome. J. Biol. Chem. 272 (1997) 58-62
16. Hayden M.R., and Tyagi S.C. A is for amylin and amyloid in type 2 diabetes mellitus. J. Pancreas 2 (2001) 124-139
17. Hayden M.R., Tyagi S.C., Kerklo M.M., and Nicolls M.R. Type 2 diabetes mellitus as a conformational disease. J. Pancreas 6 (2005) 287-302 (Online)
18. Higham C.E., Jaikaran E.T.A.S., Fraser P.E., Gross M., and Clark A. Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils. FEBS Lett. 470 (2000) 55-60
19. Hoppener J.W., Verbeek J.S., de Koning E.J., Oosterwijk C., van Hulst K.L., Visser-Vernooy H.J., Hofhuis F.M., van Gaalen S., Berends M.J., Hackeng W.H., Jansz H.S., Morris J.K., Clark A., Capel P.J., and Lips C.J. Chronic overproduction of islet amyloid polypeptide/amylin in transgenic mice: lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycaemia or hyperinsulinaemia. Diabetologia 36 (1993) 1258-1265
20. Jaikaran E.T.A.S., Higham C.E., Serpell L.C., Zurdo J., Gross M., Clark A., and Fraser P.E. Identification of novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesis. 308 (2001) 515-525
21. Janson J., Laedtke T., Parisi J.E., O'Brien P., Petersen R.C., and Butler P.C. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 53 (2004) 474-481
22. Janson J., Soeller W.C., Roche P.C., Nelson R.T., Torchia A.J., Kreutter D.K., and Butler P.C. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc. Natl. Acad. Sci. USA 93 (1996) 7283-7288
23. Jao S., Ma K., Talafous J., Orlando R., and Zagorski M.G. Trifluoroacetic acid pretreatment reproducibly disaggregates the amyloid beta-peptide. Amyloid: Int. J. Exp. Clin. Invest. 4 (1997) 240-252
24. Jimenez J.L., Guijarro J.I., Orlova E., Zurdo J., Dobson C.M., Sunde M., and Saibil H.R. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 18 (1999) 815-821
25. Koo E.H., Lansbury Jr. P.T., and Kelly J.W. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc. Natl. Acad. Sci. USA 96 (1999) 9989-9990
26. Lin C.Y., Gurlo T., Kayed R., Butler A.E., Haataja L., Glabe C.G., and Butler P.C. Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice. Diabetes 56 (2007) 1324-1332
27. Luskey K.L. Amylin expression in the pancreatic beta-cell. Adv. Exp. Med. Biol. 321 (1992) 167-169
28. Ma Z., Westermark G.T., Sakagashira S., Sanke T., Gustavsson A., Sakamoto H., Engstrom U., Nanjo K., and Westermark P. Enhanced in vitro production of amyloid-like fibrils from mutant (S20G) islet amyloid polypeptide. Amyloid 8 (2001) 242-249
29. Maynard A.J., Sharman G.J., and Searle M.S. Origin of b-hairpin stability in solution: structural and thermodynamic analysis of the folding of a model peptide supports hydrophobic stabilization in water. J. Am. Chem. Soc. 120 (1998) 1996-2007
30. Mazor Y., Gilead S., Benhar I., and Gazit E. Identification and characterization of a novel molecular-recognition and self-assembly domain within the islet amyloid polypeptide. J. Mol. Biol. 322 (2002) 1013-1024
31. Merlini G., and Bellotti V. Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349 (2003) 583-596
32. O'Nuallain B., Williams A.D., Westermark P., and Wetzel R. Seeding specificity in amyloid growth induced by heterologous fibrils. J. Biol. Chem. 279 (2004) 17490-17499
33. Pike C.J., Walencewicz-Wasserman A.J., Kosmoski J., Cribbs D.H., Glabe C.G., and Cotman C.W. Structure-activity analyses of β-amyloid peptides: contributions of the β 25-35 region to aggregation and neurotoxicity. J. Neurochem. 64 (1995) 253-265
34. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., and Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273 (1998) 32730-32738
35. Ritzel R.A., Meier J.J., Lin C.Y., Veldhuis J.D., and Butler P.C. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 56 (2007) 65-71
36. Russo C., Salis S., Dolcini V., Venezia V., Song X., Teller J.K., and Schettini G. Amino-terminal modification and tyrosine phosphorylation of carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain. Neurobiol. Dis. 8 (2001) 173-180
37. Sakagashira S., Sanke T., Hanabusa T., Shimomura H., Ohagi S., Kumagaye K.Y., Nakajima K., and Nanjo K. Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes 45 (1996) 1279-1281
38. Satheeshkumar K.S., and Jayakumar R. Conformational polymorphism of the amyloidogenic peptide homologous to residue 113-127 of the prion protein. Biophys. J. 85 (2003) 1-11
39. Scrocchi L.A., Chen Y., Wang F., Han K., Ha K., Wu L., and Fraser P.E. Inhibitors of islet amyloid polypeptide fibrillogenesis, and the treatment of type-2 diabetes. Letts. Pept. Sci. 10 (2003) 545-551
40. Serrano L. Comparison between the phi distribution of the amino acids in the protein database and NMR data indicates that amino acids have various phi propensities in the random coil conformation. J. Mol. Biol. 254 (1995) 322-333
41. Shearman M.S., Hawtin S.R., and Tailor V.J. The intracellular component of cellular 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by beta-amyloid peptides. J. Neurochem. 65 (1995) 218-227
42. Shen C.L., and Murphy R.M. Solvent effects on self-assembly of beta-amyloid peptide. Biophys. J. 69 (1995) 640-651
43. Smith L.J. Analysis of main chain torsion angles in proteins. Prediction of NMR coupling constants for native and random-coil conformations. J. Mol. Biol. 255 (1996) 494-506
44. Stefani M., and Dobson C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81 (2003) 678-699
45. Swindells M.B. A procedure for detecting structural domains in proteins. Protein Sci. 4 (1995) 103-112
46. Swindells M.B. A procedure for the automatic determination of hydrophobic cores in protein structures. Protein Sci. 4 (1995) 93-102
47. Tan X., Osmulski P.A., and Gaczynska M. Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design. Curr. Med. Chem. 13 (2006) 155-165
48. Thomas F.T., Ljung T., Henretta J., Pittman K., and Thomas J. Reversal of type II (NIDDM) diabetes by pancreas islet transplantation: an emerging new concept in pathophysiology of an enigmatic disease. Transplant. Proc. 27 (1995) 3167-3169
49. Tjernberg L.O., Callaway D.J., Tjernberg A., Hahne S., Lilliehook C., Terenius L., Thyberg J., and Nordstedt C. A molecular model of Alzheimer amyloid beta-peptide fibril formation. J. Biol. Chem. 274 (1999) 12619-12625
50. Uversky V.N., and Fink A.L. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim. Biophys. Acta 1698 (2004) 131-153
51. Verchere C.B., D'Alessio D.A., Wang S., Andrikopoulos S., and Kahn S.E. Transgenic overproduction of islet amyloid polypeptide (amylin) is not sufficient for islet amyloid formation. Horm. Metab. Res. 29 (1997) 311-316
52. Westermark P., Wernstedt C., Wialnder E., Hayden D.W., O'Brien T.D., and Johnson K.H. Amyloid fibrils in human insulinoma and islet of Langerhans of the diabetic cat are derived from o neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. USA 84 (1987) 3881-3885
53. Westermark P., Engstrom U., Johnson K., Westermark G.T., and Betsholz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 87 (1990) 5036-5040
54. Yagui K., Yamaguchi T., Kanatsuka A., Shimada F., Huang C.I., Tokuyama Y., Ohsawa H., Yamamura K., Miyazaki J., Mikata A., Yoshida S., and Makino H. Formation of islet amyloid fibrils in beta-secretory granules of transgenic mice expressing human islet amyloid polypeptide/amylin. Eur. J. Endocrinol. 132 (1995) 487-496